Core One Labs Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gareth Manderson
- Full Time Employees
- 192
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1199 West Hastings Street Vancouver BC Canada V6E 3T5
- IPO Date
- Jun 25, 2015
- Website
- core1labs.com
- Similar Companies
- Business
- Core One Labs Inc. functions as a life sciences and biotechnology enterprise, primarily dedicated to advancing research and development. The firm is actively focused on introducing psychedelic therapeutics to the market, employing both innovative delivery platforms and assisted psychotherapy. A key area of expertise involves the cGMP API grade manufacturing of biosynthetic psilocybin and other psychedelic compounds, utilizing a proprietary, cost-effective production method that maintains the natural compound's stereochemistry. The company also develops its Thinstrips technology, which creates infused oral strips designed for enhanced bioavailability and precise administration of active pharmaceutical ingredients. Additionally, Core One Labs manages a network of medical clinics, providing a setting for clinical research into psychedelic treatments for various mental health and neurological conditions. Its Akome division is engaged in developing psychedelic bio-compounds, demonstrating promising preclinical results for conditions like Alzheimer's and Parkinson's. Originally established in 2010 and situated in Vancouver, Canada, the company adopted its current name, Core One Labs Inc., in September 2019, having previously been known as Lifestyle Delivery Systems Inc.
CSE Bulletin: Delist - Core One Labs Inc. (COOL)
Core One Enters into Loan Agreement with Right Season Investments
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022
Psychedelics Company Core One Labs Dives Into Functional Mushrooms With New $3M Acquisition
Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
Core One Labs Retains Canada's Highest-Ranked IP Law Firm to Assist With Patent Filings
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq
REPEAT - Core One Labs' Biosynthesized Psilocybin Provisional Patent Imminent